Darryl T. Martin, PhD
Assistant Professor
Research & Publications
Biography
News
Research Summary
Dr. Martin’s interest encompasses both translational and biomedical research. His current research focuses on understanding the mechanisms involved in chemotherapeutic resistant bladder tumors as well as identifying the molecular signatures of heterogeneous prostate cancers. Dr. Martin uses patient derived tumors, primary cancer cells and cancer mouse models to develop novel therapies. He is currently funded by the Department of Defense to study tumor-homing nanoparticles for the imaging and treatment of prostate cancer.
Extensive Research Description
- Project 1 attempts to understand the mechanism(s) involved in chemotherapeutic resistant bladder tumors
- Project 2 aims to identify the molecular signatures of heterogeneous prostate cancers
- Project 3 uses functionalized nanoparticles to locate and treat prostate cancer
Resistant bladder tumors; Heterogeneous prostate cancers; Tumor-homing nanoparticles
Coauthors
Research Interests
Urinary Bladder Neoplasms; Inflammation; Prostatic Neoplasms; Drug Delivery Systems; Cystitis, Interstitial; Biomedical Research; Nanomedicine; Translational Research, Biomedical; Tumor Microenvironment
Selected Publications
- PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNINGEsmaili R, Khajir G, Leapman M, Sprenkle P, Martin D, Onofrey J. PD38-08 AVOIDING UNNECESSARY TARGETED PROSTATE BIOPSIES USING MACHINE LEARNING. Investigative Urology 2023, 209: e996. DOI: 10.1097/ju.0000000000003336.08.
- Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy.Choksi AU, Khan AI, Lokeshwar SD, Segal D, Weiss RM, Martin DT. Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy. American Journal Of Clinical And Experimental Urology 2022, 10: 142-153. PMID: 35874285, PMCID: PMC9301064.
- Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificityMartin DT, Lee JS, Liu Q, Galiana G, Sprenkle PC, Humphrey PA, Petrylak DP, Weinreb JC, Schulam PG, Weiss RM, Fahmy TM. Targeting prostate cancer with Clostridium perfringens enterotoxin functionalized nanoparticles co-encapsulating imaging cargo enhances magnetic resonance imaging specificity. Nanomedicine Nanotechnology Biology And Medicine 2021, 40: 102477. PMID: 34740868, DOI: 10.1016/j.nano.2021.102477.
- Knocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survivalLiu Q, Shen H, Naguib A, Weiss RM, Martin DT. Knocking down claudin receptors leads to a decrease in prostate cancer cell migration, cell growth, cell viability and clonogenic cell survival. Molecular Biomedicine 2021, 2: 31. PMID: 35006480, PMCID: PMC8607359, DOI: 10.1186/s43556-021-00053-0.
- The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-AnalysisRajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC, Ploussard G, Pradere B, Shariat SF, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Investigative Urology 2021, 206: 507-516. PMID: 33904755, DOI: 10.1097/ju.0000000000001821.
- Genome-wide association analysis reveals regulation of at-risk loci by DNA methylation in prostate cancerLiu Q, Liu G, Martin DT, Xing YT, Weiss RM, Qi J, Kang J. Genome-wide association analysis reveals regulation of at-risk loci by DNA methylation in prostate cancer. Asian Journal Of Andrology 2021, 23: 472-478. PMID: 33762478, PMCID: PMC8451484, DOI: 10.4103/aja.aja_20_21.
- Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical ProstatectomyGhabili K, Paulson N, Syed JS, Nawaf CB, Khajir G, Martin DT, Onofrey J, Leapman MS, Levi A, Weinreb JC, Humphrey PA, Sprenkle PC. Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy. Case Reports In Urology 2021, 2021: 2687416. PMID: 33936831, PMCID: PMC8054861, DOI: 10.1155/2021/2687416.
- Achieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticlesLi G, He S, Schätzlein AG, Weiss RM, Martin DT, Uchegbu IF. Achieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticles. Journal Of Controlled Release 2021, 332: 210-224. PMID: 33607176, DOI: 10.1016/j.jconrel.2021.02.007.
- Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosisHe S, Li G, Schätzlein AG, Humphrey PA, Weiss RM, Uchegbu IF, Martin DT. Down-regulation of GP130 signaling sensitizes bladder cancer to cisplatin by impairing Ku70 DNA repair signaling and promoting apoptosis. Cellular Signalling 2021, 81: 109931. PMID: 33529758, DOI: 10.1016/j.cellsig.2021.109931.
- Initial Evaluation of Rapid, Direct-to-Digital Prostate Biopsy Pathology.Torres R, Olson E, Homer R, Martin DT, Levene MJ, Perincheri S, Sprenkle PC, Humphrey PA. Initial Evaluation of Rapid, Direct-to-Digital Prostate Biopsy Pathology. Archives Of Pathology & Laboratory Medicine 2020, 145: 583-591. PMID: 32991670, DOI: 10.5858/arpa.2020-0037-oa.
- Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growthLi X, He S, Tian Y, Weiss RM, Martin DT. Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth. Cellular Signalling 2019, 63: 109381. PMID: 31374291, DOI: 10.1016/j.cellsig.2019.109381.
- Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic targetMartin DT, Shen H, Steinbach-Rankins JM, Zhu X, Johnson KK, Syed J, Saltzman WM, Weiss RM. Glycoprotein-130 expression is associated with aggressive bladder cancer and is a potential therapeutic target. Molecular Cancer Therapeutics 2019, 18: molcanther.1079.2017. PMID: 30381445, PMCID: PMC6363894, DOI: 10.1158/1535-7163.mct-17-1079.
- Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted BiopsiesMartin DT, Ghabili K, Levi A, Humphrey PA, Sprenkle PC. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies. Urology 2018, 125: 64-72. PMID: 30552940, DOI: 10.1016/j.urology.2018.12.001.
- Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive RatShimizu S, Shimizu T, Tsounapi P, Higashi Y, Martin DT, Nakamura K, Honda M, Inoue K, Saito M. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. PLOS ONE 2015, 10: e0133798. PMID: 26308715, PMCID: PMC4550428, DOI: 10.1371/journal.pone.0133798.
- Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive ratHolmström F, Shimizu S, Shimizu T, Higashi Y, Martin DT, Honda M, Saito M. Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive rat. The Prostate 2015, 75: 1774-1782. PMID: 26286428, DOI: 10.1002/pros.23063.
- Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer GrowthMartin D, Steinbach J, Saltzman W, Weiss R. Blocking Glycoprotein‐130 Pathway Decreases Bladder Cancer Growth. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.889.11.
- Blocking of the ATP sensitive potassium channel ameliorates the ischaemia‐reperfusion injury in the rat testisShimizu S, Oikawa R, Tsounapi P, Inoue K, Shimizu T, Tanaka K, Martin D, Honda M, Sejima T, Tomita S, Saito M. Blocking of the ATP sensitive potassium channel ameliorates the ischaemia‐reperfusion injury in the rat testis. Andrology 2014, 2: 458-465. PMID: 24604784, DOI: 10.1111/j.2047-2927.2014.00199.x.
- Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancerMartin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, Wheeler MA, Kelly WK, Tew GN, Saltzman WM, Weiss RM. Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine Nanotechnology Biology And Medicine 2013, 9: 1124-1134. PMID: 23764660, PMCID: PMC3815967, DOI: 10.1016/j.nano.2013.05.017.
- A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery.Hoimes C, Martin D, Kaimakliotis H, Cheng C, Kelly W, Tew G, Wheeler M, Weiss R, Saltzman W. A novel polymer-coated nanoparticle (NP) for urothelium penetration and drug delivery. Journal Of Clinical Oncology 2013, 31: e15543-e15543. DOI: 10.1200/jco.2013.31.15_suppl.e15543.
- Controlled Cell Proliferation on an Electrochemically Engineered Collagen ScaffoldGendron R, Kumar MR, Paradis H, Martin D, Ho N, Gardiner D, S. E, Poduska KM. Controlled Cell Proliferation on an Electrochemically Engineered Collagen Scaffold. Macromolecular Bioscience 2011, 12: 360-366. PMID: 22213568, DOI: 10.1002/mabi.201100341.
- Tubedown Expression Correlates with the Differentiation Status and Aggressiveness of Neuroblastic TumorsMartin DT, Gendron RL, Jarzembowski JA, Perry A, Collins MH, Pushpanathan C, Miskiewicz E, Castle VP, Paradis H. Tubedown Expression Correlates with the Differentiation Status and Aggressiveness of Neuroblastic Tumors. Clinical Cancer Research 2007, 13: 1480-1487. PMID: 17332292, DOI: 10.1158/1078-0432.ccr-06-1716.